Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

MRK

Merck (MRK)

Merck and Co Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:MRK
DateTimeSourceHeadlineSymbolCompany
05/06/202420:45Business WireMerck to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:MRKMerck and Co Inc
05/06/202405:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202405:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
05/06/202404:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
04/06/202423:10IH Market NewsEconomic Worries May Lead To Weakness On Wall StreetNYSE:MRKMerck and Co Inc
31/05/202406:39Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingNYSE:MRKMerck and Co Inc
31/05/202406:28Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:MRKMerck and Co Inc
31/05/202406:14Edgar (US Regulatory)Form 8-K - Current reportNYSE:MRKMerck and Co Inc
29/05/202423:10IH Market NewsRising Treasury Yields May Weigh On Wall StreetNYSE:MRKMerck and Co Inc
29/05/202421:34IH Market NewsRobinhood Shares Surge 3.3% on Stock Buyback Announcement; Anglo Declines BHP Deadline Extension, and More NewsNYSE:MRKMerck and Co Inc
29/05/202421:15Business WireFDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural MesotheliomaNYSE:MRKMerck and Co Inc
29/05/202420:45Business WireMerck to Acquire EyeBioNYSE:MRKMerck and Co Inc
29/05/202406:44IH Market NewsNasdaq Climbs To Another Record Closing High But Dow Sees Further DownsideNYSE:MRKMerck and Co Inc
29/05/202406:31Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:MRKMerck and Co Inc
29/05/202405:12Business WireMerck Announces Third-Quarter 2024 DividendNYSE:MRKMerck and Co Inc
28/05/202420:45Business WireMerck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)NYSE:MRKMerck and Co Inc
20/05/202420:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:MRKMerck and Co Inc
17/05/202406:15Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNYSE:MRKMerck and Co Inc
16/05/202401:31Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNYSE:MRKMerck and Co Inc
15/05/202420:45Business WireMerck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse PipelineNYSE:MRKMerck and Co Inc
13/05/202420:45Business WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk MelanomaNYSE:MRKMerck and Co Inc
09/05/202421:05PR Newswire (Canada)Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapyNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK